EP4712957A2 - Isoandrographolidanaloga und behandlungsverfahren damit - Google Patents

Isoandrographolidanaloga und behandlungsverfahren damit

Info

Publication number
EP4712957A2
EP4712957A2 EP24808232.3A EP24808232A EP4712957A2 EP 4712957 A2 EP4712957 A2 EP 4712957A2 EP 24808232 A EP24808232 A EP 24808232A EP 4712957 A2 EP4712957 A2 EP 4712957A2
Authority
EP
European Patent Office
Prior art keywords
compound
disease
formula
condition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24808232.3A
Other languages
English (en)
French (fr)
Inventor
Subbaraju Venkata Gottumukkala
Kiran CHERUKUPALLI
Bryan Hurst Norman
Prabhakar K JADHAV
Sotirios K KARATHANASIS
Goutam Mandal
Indranil Mukhopadhyay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enveda Therapeutics Inc
Original Assignee
Enveda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enveda Therapeutics Inc filed Critical Enveda Therapeutics Inc
Publication of EP4712957A2 publication Critical patent/EP4712957A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24808232.3A 2023-05-18 2024-05-17 Isoandrographolidanaloga und behandlungsverfahren damit Pending EP4712957A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503156P 2023-05-18 2023-05-18
PCT/US2024/030111 WO2024239001A2 (en) 2023-05-18 2024-05-17 Isoandrographolide analogs and method for treatment using the same

Publications (1)

Publication Number Publication Date
EP4712957A2 true EP4712957A2 (de) 2026-03-25

Family

ID=93519990

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24808232.3A Pending EP4712957A2 (de) 2023-05-18 2024-05-17 Isoandrographolidanaloga und behandlungsverfahren damit

Country Status (12)

Country Link
EP (1) EP4712957A2 (de)
JP (1) JP2026521119A (de)
KR (1) KR20260026485A (de)
CN (1) CN121532179A (de)
AU (1) AU2024271399A1 (de)
CL (1) CL2025003577A1 (de)
IL (1) IL324630A (de)
JO (1) JOP20250284A1 (de)
MX (1) MX2025013734A (de)
PE (1) PE20260566A1 (de)
TW (1) TW202509038A (de)
WO (1) WO2024239001A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4376396A (en) * 1994-12-06 1996-06-26 Paracelsian, Inc. Use of andrographolide compounds to treat or prevent pathogenicity of diseases
CN101028260A (zh) * 2007-02-06 2007-09-05 中国药科大学 取代的异穿心莲内酯衍生物的用途
PL2897608T3 (pl) * 2013-04-22 2019-07-31 Innobioscience, Llc Leczenie choroby Alzheimera i zaburzeń poznawczych za pomocą andrografolidów
US10064841B1 (en) * 2018-01-08 2018-09-04 King Saud University Isoandrographolide-19-propionate for treatment of non-alcoholic fatty liver disease (NAFLD)
WO2019166003A1 (zh) * 2018-03-02 2019-09-06 郑州大学 14-脱氧-11,12-脱氢-8,12-环氧或7,8-烯-穿心莲内酯及其15位取代衍生物和用途

Also Published As

Publication number Publication date
KR20260026485A (ko) 2026-02-26
TW202509038A (zh) 2025-03-01
CN121532179A (zh) 2026-02-13
JOP20250284A1 (ar) 2025-11-16
CL2025003577A1 (es) 2026-04-06
AU2024271399A1 (en) 2025-12-18
JP2026521119A (ja) 2026-06-26
WO2024239001A2 (en) 2024-11-21
PE20260566A1 (es) 2026-03-10
MX2025013734A (es) 2026-03-02
WO2024239001A3 (en) 2025-03-06
IL324630A (en) 2026-01-01

Similar Documents

Publication Publication Date Title
US20070191462A1 (en) Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
JP6337109B2 (ja) ナトリウムチャネルの調節剤としてのスルホンアミド
JP6463580B2 (ja) ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
US7960407B2 (en) Crystal forms of an imidazole derivative
CN105073738A (zh) 作为钠通道调节剂的喹啉及喹唑啉酰胺类
US20090227562A1 (en) Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
MX2015006270A (es) Formas polimorfas.
JP2024526952A (ja) 結晶形
WO2015178020A1 (en) Benzisoxazole derivative salt
AU2024271399A1 (en) Isoandrographolide analogs and method for treatment using the same
WO2025155874A1 (en) Methods and compounds for modulating immune response
EP1791599A1 (de) Kombination aus einem 5-ht(1) rezeptor-agonisten und einem alpha-2-delta-liganden zur behandlung von migräne
WO2006056874A1 (en) Salt form
JP2009515943A (ja) アミノ酸誘導体
WO2024239000A2 (en) G-protein coupled receptor antagonist
US20080293746A1 (en) Combinations comprising pregabalin
US20090286875A1 (en) Isocystene derivatives for the treatment of pain
OA18626A (en) Sulfonamides as modulators of sodium channels.
WO2009136375A1 (en) Treatment of interstitial cystitis
HK1108831A (en) Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR